We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Novo-N.Dkk1'b' | LSE:NVOB | London | Ordinary Share | DK0060102614 | DKK1 SER'B' |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMNVOB Novo Nordisk A/S - Share repurchase programme On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010. Since the announcement as of 15 February 2010, the following transactions have been made under the programme: Number of shares Average purchase Transaction value, price DKK Accumulated, last 885,000 331,984,754 announcement 15 February 2010 75,000 391.0200 29,326,500 16 February 2010 90,000 391.3800 35,224,200 17 February 2010 90,000 392.8600 35,357,400 18 February 2010 75,000 393.4850 29,511,375 19 February 2010 90,000 394.1670 35,475,030 Accumulated under the 1,305,000 496,879,259 programme Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 125,650 B shares in the period from 15 February 2010 to 19 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme. With the transactions stated above, Novo Nordisk owns a total of 31,576,298 treasury shares, corresponding to 5.1% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Mette Kruse Danielsen Klaus Bülow Davidsen Tel: (+45) 4442 3883 Tel: (+45) 4442 3176 mkd@novonordisk.com klda@novonordisk.com <mailto:mkd@novonordisk.com> <mailto:klda@novonordisk.com> Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com <mailto:krop@novonordisk.com> In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com <mailto:secl@novonordisk.com> <mailto:hrmm@novonordisk.com> Company Announcement no 10 / 2010 [HUG#1387085] Company Announcement no 10 2010: http://hugin.info/2013/R/1387085/345487.pdf
1 Year Novo-N.Dkk1'b' Chart |
1 Month Novo-N.Dkk1'b' Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions